Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099223 | 0.83 | PAX8 (0.41) | MAPTAURKARPS6KB1CYP2C19ALOX5 | |
| SCHEMBL15528795 | 0.82 | MAPT (0.36) | MAPTAURKARPS6KB1CYP2C19ALOX5 | |
| SCHEMBL1097623 | 0.80 | MLYCD (0.39) | MAPTAURKARPS6KB1CYP2C19SMN1; SMN2 | |
| SCHEMBL1099493 | 0.79 | USP30 (0.43) | USP30SMN1; SMN2OXTR | |
| SCHEMBL1097539 | 0.78 | F2 (0.36) | MAPTAURKARPS6KB1CYP2C19SMN1; SMN2 | |
| SCHEMBL1098848 | 0.78 | MAPT (0.36) | MAPTCYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL26626463 | 0.78 | CYP2C19 (0.47) | USP30MAPTCYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL1794562 | 0.76 | F2 (0.39) | MAPTAURKARPS6KB1CYP2C19SMN1; SMN2 | |
| SCHEMBL12185886 | 0.74 | PAX8 (0.39) | MAPTSMN1; SMN2RAB9A | |
| SCHEMBL30182335 | 0.73 | GRM2 (0.38) | MAPTCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | USP30 3950/4885MAPT 3010/4885AURKA 1397/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | USP30 3993/4885MAPT 2983/4885AURKA 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.